Literature DB >> 20120699

The age-18 redetermination and postredetermination participation in SSI.

Jeffrey Hemmeter1, Elaine Gilby.   

Abstract

Youth who initially become eligible for Supplemental Security Income under the definition of disability for children must have their eligibility redetermined upon attaining age 18, using the definition of disability for adults. Based on 8 years of administrative data from the Social Security Administration, this article provides statistics on the average age-18 redetermination outcomes over time by various individual characteristics. We find little change in the initial cessation rate for all groups over time, although there are large differences in initial cessation rates between disability type and other characteristics. The majority of redeterminations result in initial continuances. The article also examines data on individuals who successfully appeal an initial cessation determination and/or who successfully reapply for payments after losing eligibility. Many youth initially found not to meet the definition of disability for adults successfully appeal that decision, and a nontrivial number who lost eligibility successfully reapply at a later date.

Entities:  

Mesh:

Year:  2009        PMID: 20120699

Source DB:  PubMed          Journal:  Soc Secur Bull        ISSN: 0037-7910


  3 in total

1.  Health-related unmet needs of supplemental security income youth after the age-18 redetermination.

Authors:  Jeffrey Hemmeter
Journal:  Health Serv Res       Date:  2011-02-09       Impact factor: 3.402

2.  Understanding the Disability Dynamics of Youth: Health Condition and Limitation Changes for Youth and Their Influence on Longitudinal Survey Attrition.

Authors:  David R Mann; Todd Honeycutt
Journal:  Demography       Date:  2016-06

3.  Potential savings from redetermining disability among children receiving supplemental security income benefits.

Authors:  Christian D Pulcini; Milton Kotelchuck; Karen A Kuhlthau; Alixandra A Nozzolillo; James M Perrin
Journal:  Acad Pediatr       Date:  2012-09-16       Impact factor: 3.107

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.